San Diego, CA, United States of America

Alex Aravanis

This inventor holds 30 USPTO granted patents and 23 published patent applications, plus 6 CIPO patents and 21 EPO patents, primarily in Nucleic Acid Analysis. Top assignees: Illumina Corporation, Sapphire Energy, Inc., Spatial Transcriptomics Ab. Active years: 2011-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Alex Aravanis. Retrieved from https://idiyas.com/inventor/alex-aravanis

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 30 

% Patents Active = 73.3

 

 

Average Co-Inventor Count = 4.4

ph-index = 8

Forward Citations = 945(Granted Patents)


Location History:

  • Foster City, CA (US) (2018)
  • San Diego, CA (US) (2011 - 2023)
  • San Francisco, CA (US) (2019 - 2023)
  • San Mateo, CA (US) (2019 - 2024)

Company Filing History:


Years Active: 2011-2026

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Nucleic Acid Sequencing
Error Suppression
Library Preparation
Biochemical Analysis
Mutated Cell Free Nucleic Acids
CRISPR-Cas Systems
Rotary Valve
Spatially Distinguished Analysis
Amplicon Preparation
Unique Molecular Indices
Biomass Recovery
Hydrocarbon Refining
30 patents (USPTO):Explore Patents

Title: Alex Aravanis: Innovator in Biochemical Analysis

Introduction

Alex Aravanis is a prominent inventor based in San Diego, California, known for his significant contributions to the field of biochemical analysis. With an impressive portfolio of 28 patents, he has developed innovative systems and methods that enhance the capabilities of biological sample analysis.

Latest Patents

Among his latest patents are groundbreaking technologies that streamline biochemical processes. The first patent involves systems and methods for biochemical analysis, which include a base instrument and a removable cartridge. This innovative cartridge contains a fluidic network designed to receive and direct biological samples through designated reactions. It features a flow-control valve that can be adjusted to regulate the sample's movement. The removable cartridge is designed to engage seamlessly with the base instrument, which contains a valve actuator, ensuring precise control during analysis. Additionally, a detection assembly integrated into the cartridge or base instrument facilitates the observation of the reactions.

Another notable patent addresses error suppression in sequenced DNA fragments by utilizing redundant reads with unique molecular indices (UMIs). This technology enables accurate determination of sequences associated with individual polynucleotide fragments, even in complex scenarios involving low allele frequencies and extended sequence lengths. By incorporating both physical and virtual UMIs, this innovation revolutionizes the reliability of DNA sequencing.

Career Highlights

Throughout his career, Alex has collaborated with influential companies in the biotech sector. He has held key positions at Illumina Corporation, a leader in genomic sequencing technology, and Sapphire Energy, Inc., which focuses on sustainable algae-based fuels. His experiences in these esteemed organizations have significantly influenced his inventive pursuits and advancements in biochemistry.

Collaborations

Working alongside accomplished professionals has played a pivotal role in Alex's career. Notable collaborators include Gordon M. Cann and Leila Bazargan, whose collective expertise has fostered innovation and solution-driven research in their projects.

Conclusion

Alex Aravanis stands out as a pioneering inventor whose contributions to biochemical analysis have transformed the scientific landscape. His advancements through various patents, coupled with his collaborative efforts in top-tier organizations, continue to inspire the future of biological research and technology.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…